Phentolaine mesylate inj
Products billed under this code include Phentolamine Mesylate.
Payment limit per 5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Phentolamine Mesylate.
Payment limit per 5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Phentolamine Mesylate | Hikma Pharmaceuticals USA Inc. | 00143-9564-01 | 1 | $296.849 |
| Phentolamine Mesylate | Hikma Pharmaceuticals USA Inc. | 00143-9564-10 | 10 | $2,968.49 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $296.849 | +$8.224 | 5 MG | Phentolaine mesylate inj | v1, posted September 17, 2026 |
| 3Q26 | $288.625 | +$31.176 | 5 MG | Phentolaine mesylate inj | v1, posted September 15, 2026 |
| 2Q26 | $257.449 | −$163.109 | 5 MG | Phentolaine mesylate inj | v1, posted September 15, 2026 |
| 1Q26 | $420.558 | −$11.464 | 5 MG | Phentolaine mesylate inj | v1, posted September 15, 2026 |
| 4Q25 | $432.022 | −$4.485 | 5 MG | Phentolaine mesylate inj | v1, posted September 8, 2026 |
| 3Q25 | $436.507 | −$12.792 | 5 MG | Phentolaine mesylate inj | v1, posted March 10, 2026 |
| 2Q25 | $449.299 | +$54.674 | 5 MG | Phentolaine mesylate inj | v1, posted March 10, 2026 |
| 1Q25 | $394.625 | +$27.504 | 5 MG | Phentolaine mesylate inj | v1, posted December 19, 2025 |
| 4Q24 | $367.121 | −$32.213 | 5 MG | Phentolaine mesylate inj | v1, posted June 11, 2025 |
| 3Q24 | $399.334 | −$44.983 | 5 MG | Phentolaine mesylate inj | v1, posted June 11, 2025 |
| 2Q24 | $444.317 | −$2.48 | 5 MG | Phentolaine mesylate inj | v1, posted March 11, 2025 |
| 1Q24 | $446.797 | −$6.862 | 5 MG | Phentolaine mesylate inj | v1, posted December 19, 2024 |
| 4Q23 | $453.659 | −$4.523 | 5 MG | Phentolaine mesylate inj | v1, posted October 10, 2024 |
| 3Q23 | $458.182 | +$5.765 | 5 MG | Phentolaine mesylate inj | v1, posted June 5, 2024 |
| 2Q23 | $452.417 | +$2.062 | 5 MG | Phentolaine mesylate inj | v1, posted February 23, 2024 |
| 1Q23 | $450.355 | +$36.881 | 5 MG | Phentolaine mesylate inj | v1, posted December 6, 2023 |
| 4Q22 | $413.474 | +$20.795 | 5 MG | Phentolaine mesylate inj | v1, posted June 22, 2023 |
| 3Q22 | $392.679 | +$14.949 | 5 MG | Phentolaine mesylate inj | v1, posted June 9, 2023 |
| 2Q22 | $377.73 | −$36.385 | 5 MG | Phentolaine mesylate inj | v1, posted December 14, 2022 |
| 1Q22 | $414.115 | −$1.886 | 5 MG | Phentolaine mesylate inj | v1, posted June 8, 2022 |
| 4Q21 | $416.001 | +$6.448 | 5 MG | Phentolaine mesylate inj | v1, posted June 2, 2022 |
| 3Q21 | $409.553 | −$3.802 | 5 MG | Phentolaine mesylate inj | v1, posted June 2, 2022 |
| 2Q21 | $413.355 | +$56.471 | 5 MG | Phentolaine mesylate inj | v1, posted March 1, 2022 |
| 1Q21 | $356.884 | – | 5 MG | Phentolaine mesylate inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.